{"transactions":[{"id":713050,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-08T20:57:19.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."}],"balance_after":75000,"derivative":{"exercise_price":6.78,"underlying":"ADSs","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001213900-26-076426","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026076426/ownership.xml","form_type":"4"}},{"id":2255764,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:23:32.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":474629,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":4.42,"underlying":"Common Stock","underlying_shares":474629},"source":{"system":"sec-edgar","filing":"0000899243-22-019783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019783/doc4.xml","form_type":"4"}},{"id":2255763,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:23:32.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":776617,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.73,"underlying":"Common Stock","underlying_shares":776617},"source":{"system":"sec-edgar","filing":"0000899243-22-019783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019783/doc4.xml","form_type":"4"}},{"id":2255762,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:23:32.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":567423,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.92,"underlying":"Common Stock","underlying_shares":567423},"source":{"system":"sec-edgar","filing":"0000899243-22-019783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019783/doc4.xml","form_type":"4"}},{"id":2255761,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:23:32.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":591510,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.7,"underlying":"Common Stock","underlying_shares":591510},"source":{"system":"sec-edgar","filing":"0000899243-22-019783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019783/doc4.xml","form_type":"4"}},{"id":2255760,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:23:32.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":725751,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.66,"underlying":"Common Stock","underlying_shares":725751},"source":{"system":"sec-edgar","filing":"0000899243-22-019783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019783/doc4.xml","form_type":"4"}},{"id":2255759,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:23:32.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":773700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":1.12,"underlying":"Common Stock","underlying_shares":773700},"source":{"system":"sec-edgar","filing":"0000899243-22-019783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019783/doc4.xml","form_type":"4"}},{"id":2255758,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:23:32.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":288786,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.18,"underlying":"Common Stock","underlying_shares":288786},"source":{"system":"sec-edgar","filing":"0000899243-22-019783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019783/doc4.xml","form_type":"4"}},{"id":2255757,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:23:32.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":56300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":3.09,"underlying":"Common Stock","underlying_shares":56300},"source":{"system":"sec-edgar","filing":"0000899243-22-019783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019783/doc4.xml","form_type":"4"}},{"id":2255756,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T17:23:32.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":21658,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Company option to purchase Shares (\"Company Option\") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option."}],"balance_after":0,"derivative":{"exercise_price":4.26,"underlying":"Common Stock","underlying_shares":21658},"source":{"system":"sec-edgar","filing":"0000899243-22-019783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019783/doc4.xml","form_type":"4"}},{"id":2255755,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-05-26T17:23:32.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":374099,"price":5.6,"value":2094954.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each Company performance restricted stock unit (\"Company PSU\") means any performance stock unit granted under the Company Equity Plan. At the Effective Time, each Company PSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company PSU (at the target level of performance) immediately prior to the Effective Time multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the \"Company\"),  Halozyme Therapeutics, Inc., a Delaware corporation (\"Parent\"), and Atlas Merger Sub, Inc., a Delaware corporation (\"Purchaser\") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 24, 2022 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the \"Merger Consideration\") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-019783","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019783/doc4.xml","form_type":"4"}},{"id":2255754,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-05-26T17:23:32.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":611667,"price":5.6,"value":3425335.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Each Company restricted stock unit (\"Company RSU\") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the \"Company\"),  Halozyme Therapeutics, Inc., a Delaware corporation (\"Parent\"), and Atlas Merger Sub, Inc., a Delaware corporation (\"Purchaser\") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 24, 2022 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the \"Merger Consideration\") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-019783","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019783/doc4.xml","form_type":"4"}},{"id":2255753,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-05-26T17:23:32.000Z","date":"2022-05-24","kind":"disposition_to_issuer","acquired":false,"shares":1876693,"price":5.6,"value":10509480.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the \"Company\"),  Halozyme Therapeutics, Inc., a Delaware corporation (\"Parent\"), and Atlas Merger Sub, Inc., a Delaware corporation (\"Purchaser\") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 24, 2022 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the \"Merger Consideration\") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-019783","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000089924322019783/doc4.xml","form_type":"4"}},{"id":2351264,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-03-04T18:38:43.000Z","date":"2022-03-03","kind":"tax_withholding","acquired":false,"shares":37695,"price":3.8,"value":143241.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 13, 2019, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 3, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":2488360,"source":{"system":"sec-edgar","filing":"0001016169-22-000035","document":"wf-form4_164643709286132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000101616922000035/wf-form4_164643709286132.xml","form_type":"4"}},{"id":2351263,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-03-04T18:38:43.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":86814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 13, 2019, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 3, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":2526055,"source":{"system":"sec-edgar","filing":"0001016169-22-000035","document":"wf-form4_164643709286132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000101616922000035/wf-form4_164643709286132.xml","form_type":"4"}},{"id":2386286,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-18T19:13:18.000Z","date":"2022-02-16","kind":"tax_withholding","acquired":false,"shares":34282,"price":3.66,"value":125472.12,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 13, 2019, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on February 16, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":2439241,"source":{"system":"sec-edgar","filing":"0001016169-22-000012","document":"wf-form4_164522957417097.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000101616922000012/wf-form4_164522957417097.xml","form_type":"4"}},{"id":2386285,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-18T19:13:18.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":76893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 13, 2019, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on February 16, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":2473523,"source":{"system":"sec-edgar","filing":"0001016169-22-000012","document":"wf-form4_164522957417097.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000101616922000012/wf-form4_164522957417097.xml","form_type":"4"}},{"id":2670739,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T18:20:26.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":474629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date."}],"balance_after":474629,"derivative":{"exercise_price":4.42,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":474629},"source":{"system":"sec-edgar","filing":"0001209191-21-040326","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121040326/doc4.xml","form_type":"4"}},{"id":2670738,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-06-14T18:20:26.000Z","date":"2021-06-13","kind":"tax_withholding","acquired":false,"shares":40892,"price":4.45,"value":181969.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":2396630,"source":{"system":"sec-edgar","filing":"0001209191-21-040326","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121040326/doc4.xml","form_type":"4"}},{"id":2670737,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-06-14T18:20:26.000Z","date":"2021-06-11","kind":"tax_withholding","acquired":false,"shares":58317,"price":4.45,"value":259510.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":2437522,"source":{"system":"sec-edgar","filing":"0001209191-21-040326","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121040326/doc4.xml","form_type":"4"}},{"id":2670736,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-06-14T18:20:26.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":248869,"price":4.42,"value":1100000.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant."}],"balance_after":2495839,"source":{"system":"sec-edgar","filing":"0001209191-21-040326","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121040326/doc4.xml","form_type":"4"}},{"id":2674487,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-06-10T17:37:57.000Z","date":"2021-06-08","kind":"tax_withholding","acquired":false,"shares":44223,"price":4.39,"value":194138.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":2246970,"source":{"system":"sec-edgar","filing":"0001209191-21-039590","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121039590/doc4.xml","form_type":"4"}},{"id":2815888,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-03-03T18:31:05.000Z","date":"2021-03-01","kind":"tax_withholding","acquired":false,"shares":66330,"price":4.5,"value":298485.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 8, 2018, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 1, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":2291193,"source":{"system":"sec-edgar","filing":"0001209191-21-017260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121017260/doc4.xml","form_type":"4"}},{"id":2815887,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-03-03T18:31:05.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":152763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 8, 2018, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 1, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":2357523,"source":{"system":"sec-edgar","filing":"0001209191-21-017260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121017260/doc4.xml","form_type":"4"}},{"id":2847117,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-19T19:11:08.000Z","date":"2021-02-18","kind":"exercise","acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vested in equal quarterly installments over three years from the grant date of March 10, 2016."}],"balance_after":0,"derivative":{"exercise_price":0.88,"expiration_date":"2026-03-09","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-21-012547","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012547/doc4.xml","form_type":"4"}},{"id":2847116,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-19T19:11:08.000Z","date":"2021-02-17","kind":"exercise","acquired":false,"shares":5519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in equal quarterly installments over one year from the grant date of March 10, 2015."}],"balance_after":0,"derivative":{"exercise_price":2.62,"expiration_date":"2025-03-09","underlying":"Common Stock","underlying_shares":5519},"source":{"system":"sec-edgar","filing":"0001209191-21-012547","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012547/doc4.xml","form_type":"4"}},{"id":2847115,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-19T19:11:08.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":241960,"price":5,"value":1209800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale of common stock was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2204760,"source":{"system":"sec-edgar","filing":"0001209191-21-012547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012547/doc4.xml","form_type":"4"}},{"id":2847114,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-19T19:11:08.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":17844,"price":5.01,"value":89398.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2446720,"source":{"system":"sec-edgar","filing":"0001209191-21-012547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012547/doc4.xml","form_type":"4"}},{"id":2847113,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-19T19:11:08.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":232156,"price":5,"value":1160780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2464564,"source":{"system":"sec-edgar","filing":"0001209191-21-012547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012547/doc4.xml","form_type":"4"}},{"id":2847112,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-19T19:11:08.000Z","date":"2021-02-18","kind":"exercise","acquired":true,"shares":250000,"price":0.88,"value":220000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2696720,"source":{"system":"sec-edgar","filing":"0001209191-21-012547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012547/doc4.xml","form_type":"4"}},{"id":2847111,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-19T19:11:08.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":5519,"price":4.75,"value":26215.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2446720,"source":{"system":"sec-edgar","filing":"0001209191-21-012547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012547/doc4.xml","form_type":"4"}},{"id":2847110,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-19T19:11:08.000Z","date":"2021-02-17","kind":"exercise","acquired":true,"shares":5519,"price":2.62,"value":14459.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2452239,"source":{"system":"sec-edgar","filing":"0001209191-21-012547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012547/doc4.xml","form_type":"4"}},{"id":2847109,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-19T19:11:08.000Z","date":"2021-02-17","kind":"tax_withholding","acquired":false,"shares":116313,"price":4.73,"value":550160.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 8, 2018, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, which was certified and vested on February 17, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":2446720,"source":{"system":"sec-edgar","filing":"0001209191-21-012547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012547/doc4.xml","form_type":"4"}},{"id":2847108,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-19T19:11:08.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":267878,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 8, 2018, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, which was certified and vested on February 17, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold."}],"balance_after":2563033,"source":{"system":"sec-edgar","filing":"0001209191-21-012547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121012547/doc4.xml","form_type":"4"}},{"id":2869989,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-10T20:11:40.000Z","date":"2021-02-10","kind":"exercise","acquired":false,"shares":7278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested in equal quarterly installments over one year from the grant date of March 10, 2015."}],"balance_after":0,"derivative":{"exercise_price":2.62,"expiration_date":"2025-03-09","underlying":"Common Stock","underlying_shares":12797},"source":{"system":"sec-edgar","filing":"0001209191-21-009464","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121009464/doc4.xml","form_type":"4"}},{"id":2869988,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-10T20:11:40.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":49129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested in equal quarterly installments over one year from the grant date of March 10, 2015."}],"balance_after":0,"derivative":{"exercise_price":2.62,"expiration_date":"2025-03-09","underlying":"Common Stock","underlying_shares":49129},"source":{"system":"sec-edgar","filing":"0001209191-21-009464","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121009464/doc4.xml","form_type":"4"}},{"id":2869987,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-10T20:11:40.000Z","date":"2021-02-08","kind":"exercise","acquired":false,"shares":33574,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested in equal quarterly installments over one year from the grant date of March 10, 2015."}],"balance_after":0,"derivative":{"exercise_price":2.62,"expiration_date":"2025-03-09","underlying":"Common Stock","underlying_shares":33574},"source":{"system":"sec-edgar","filing":"0001209191-21-009464","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121009464/doc4.xml","form_type":"4"}},{"id":2869986,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-10T20:11:40.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":7278,"price":4.75,"value":34570.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2295155,"source":{"system":"sec-edgar","filing":"0001209191-21-009464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121009464/doc4.xml","form_type":"4"}},{"id":2869985,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-10T20:11:40.000Z","date":"2021-02-10","kind":"exercise","acquired":true,"shares":7278,"price":2.62,"value":19068.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2302433,"source":{"system":"sec-edgar","filing":"0001209191-21-009464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121009464/doc4.xml","form_type":"4"}},{"id":2869984,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-10T20:11:40.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":49129,"price":4.75,"value":233362.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2295155,"source":{"system":"sec-edgar","filing":"0001209191-21-009464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121009464/doc4.xml","form_type":"4"}},{"id":2869983,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-10T20:11:40.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":49129,"price":2.62,"value":128717.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2344284,"source":{"system":"sec-edgar","filing":"0001209191-21-009464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121009464/doc4.xml","form_type":"4"}},{"id":2869982,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-10T20:11:40.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":33574,"price":4.75,"value":159476.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2295155,"source":{"system":"sec-edgar","filing":"0001209191-21-009464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121009464/doc4.xml","form_type":"4"}},{"id":2869981,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-10T20:11:40.000Z","date":"2021-02-08","kind":"exercise","acquired":true,"shares":33574,"price":2.62,"value":87963.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2328729,"source":{"system":"sec-edgar","filing":"0001209191-21-009464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919121009464/doc4.xml","form_type":"4"}},{"id":3110950,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-15T19:12:34.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":776617,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date."}],"balance_after":776617,"derivative":{"exercise_price":2.73,"expiration_date":"2030-06-11","underlying":"Common Stock","underlying_shares":776617},"source":{"system":"sec-edgar","filing":"0001209191-20-036786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120036786/doc4.xml","form_type":"4"}},{"id":3110949,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-06-15T19:12:34.000Z","date":"2020-06-13","kind":"tax_withholding","acquired":false,"shares":40892,"price":2.78,"value":113679.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":2295155,"source":{"system":"sec-edgar","filing":"0001209191-20-036786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120036786/doc4.xml","form_type":"4"}},{"id":3110948,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-06-15T19:12:34.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":402930,"price":2.73,"value":1099998.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant."}],"balance_after":2336047,"source":{"system":"sec-edgar","filing":"0001209191-20-036786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120036786/doc4.xml","form_type":"4"}},{"id":3117303,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-06-09T18:24:32.000Z","date":"2020-06-08","kind":"tax_withholding","acquired":false,"shares":44223,"price":3.13,"value":138417.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":1933117,"source":{"system":"sec-edgar","filing":"0001209191-20-035377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120035377/doc4.xml","form_type":"4"}},{"id":3117302,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-06-09T18:24:32.000Z","date":"2020-06-07","kind":"tax_withholding","acquired":false,"shares":48936,"price":3.12,"value":152680.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":1977340,"source":{"system":"sec-edgar","filing":"0001209191-20-035377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120035377/doc4.xml","form_type":"4"}},{"id":3257415,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-02-21T18:24:06.000Z","date":"2020-02-19","kind":"tax_withholding","acquired":false,"shares":90397,"price":3.53,"value":319101.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 25, 2017, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2019. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 19, 2020. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award."}],"balance_after":2026276,"source":{"system":"sec-edgar","filing":"0001209191-20-011709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120011709/doc4.xml","form_type":"4"}},{"id":3257414,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-02-21T18:24:06.000Z","date":"2020-02-19","kind":"grant","acquired":true,"shares":210782,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 25, 2017, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2019. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 19, 2020. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award."}],"balance_after":2116673,"source":{"system":"sec-edgar","filing":"0001209191-20-011709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919120011709/doc4.xml","form_type":"4"}},{"id":3345740,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-10","kind":"exercise","acquired":false,"shares":58524,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested and became exercisable in equal quarterly installments over the three-year period following the grant date of May 22, 2013."}],"balance_after":0,"derivative":{"exercise_price":3.96,"expiration_date":"2023-05-21","underlying":"Common Stock","underlying_shares":58524},"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345739,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-09","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested and became exercisable in equal quarterly installments over the three-year period following the grant date of May 22, 2013."}],"balance_after":0,"derivative":{"exercise_price":3.96,"expiration_date":"2023-05-21","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345738,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-09","kind":"exercise","acquired":false,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested and became exercisable in equal quarterly installments over the three-year period following the grant date of May 17, 2012."}],"balance_after":0,"derivative":{"exercise_price":2.94,"expiration_date":"2022-05-16","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345737,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-09","kind":"exercise","acquired":false,"shares":97000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested and became exercisable in equal quarterly installments over the three-year period following the grant date of May 17, 2011."}],"balance_after":0,"derivative":{"exercise_price":1.66,"expiration_date":"2021-05-16","underlying":"Common Stock","underlying_shares":97000},"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345736,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-09","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vested and became exercisable in equal quarterly installments over the three-year period following the grant date of November 11, 2010."}],"balance_after":0,"derivative":{"exercise_price":1.52,"expiration_date":"2020-11-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345735,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-10","kind":"sale","acquired":false,"shares":58524,"price":4.7563,"value":278357.7012,"ownership":{"direct":true},"balance_after":1905891,"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345734,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-10","kind":"exercise","acquired":true,"shares":58524,"price":3.96,"value":231755.04,"ownership":{"direct":true},"balance_after":1964415,"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345733,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":1000,"price":4.75,"value":4750.0,"ownership":{"direct":true},"balance_after":1905891,"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345732,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-09","kind":"exercise","acquired":true,"shares":1000,"price":3.96,"value":3960.0,"ownership":{"direct":true},"balance_after":1906891,"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345731,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":110000,"price":4.5766,"value":503426.0,"ownership":{"direct":true},"balance_after":1905891,"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345730,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-09","kind":"exercise","acquired":true,"shares":110000,"price":2.94,"value":323400.0,"ownership":{"direct":true},"balance_after":2015891,"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345729,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":97000,"price":4.6228,"value":448411.6,"ownership":{"direct":true},"balance_after":1905891,"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345728,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-09","kind":"exercise","acquired":true,"shares":97000,"price":1.66,"value":161020.0,"ownership":{"direct":true},"balance_after":2002891,"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345727,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":100000,"price":4.6783,"value":467830.0,"ownership":{"direct":true},"balance_after":1905891,"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3345726,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-11T19:15:34.000Z","date":"2019-12-09","kind":"exercise","acquired":true,"shares":100000,"price":1.52,"value":152000.0,"ownership":{"direct":true},"balance_after":2005891,"source":{"system":"sec-edgar","filing":"0001209191-19-060108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119060108/doc4.xml","form_type":"4"}},{"id":3373307,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-13T17:32:43.000Z","date":"2019-11-11","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested and became exercisable in equal quarterly installments over the three-year period following the grant date of November 12, 2009, and were due to expire on November 11, 2019."}],"balance_after":0,"derivative":{"exercise_price":1.1,"expiration_date":"2019-11-11","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-056440","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119056440/doc4.xml","form_type":"4"}},{"id":3373306,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-11-13T17:32:43.000Z","date":"2019-11-11","kind":"tax_withholding","acquired":false,"shares":43445,"price":3.77,"value":163787.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to cover payment of exercise price and tax liability for the underlying stock options that were exercised and held."}],"balance_after":1905891,"source":{"system":"sec-edgar","filing":"0001209191-19-056440","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119056440/doc4.xml","form_type":"4"}},{"id":3373305,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-11-13T17:32:43.000Z","date":"2019-11-11","kind":"exercise","acquired":true,"shares":100000,"price":1.1,"value":110000.0,"ownership":{"direct":true},"balance_after":1949336,"source":{"system":"sec-edgar","filing":"0001209191-19-056440","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119056440/doc4.xml","form_type":"4"}},{"id":3490468,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T17:28:41.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":567423,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date."}],"balance_after":567423,"derivative":{"exercise_price":2.92,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":567423},"source":{"system":"sec-edgar","filing":"0001209191-19-037209","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119037209/doc4.xml","form_type":"4"}},{"id":3490467,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-06-14T17:28:41.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":282534,"price":2.92,"value":824999.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant."}],"balance_after":1849336,"source":{"system":"sec-edgar","filing":"0001209191-19-037209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119037209/doc4.xml","form_type":"4"}},{"id":3494758,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-06-11T17:38:05.000Z","date":"2019-06-08","kind":"tax_withholding","acquired":false,"shares":44225,"price":2.81,"value":124272.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":1566802,"source":{"system":"sec-edgar","filing":"0001209191-19-036134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119036134/doc4.xml","form_type":"4"}},{"id":3494757,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-06-11T17:38:05.000Z","date":"2019-06-07","kind":"tax_withholding","acquired":false,"shares":48936,"price":2.81,"value":137510.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents the payment of tax liability using a portion of securities received from the company in connection with the vesting of a previously granted restricted stock unit award.  The shares of common stock reported herein were withheld by the company to cover tax liability and not actually sold."}],"balance_after":1611027,"source":{"system":"sec-edgar","filing":"0001209191-19-036134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119036134/doc4.xml","form_type":"4"}},{"id":3503181,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-06-04T17:14:24.000Z","date":"2019-06-02","kind":"tax_withholding","acquired":false,"shares":52559,"price":2.79,"value":146639.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award."}],"balance_after":1659963,"source":{"system":"sec-edgar","filing":"0001209191-19-034416","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119034416/doc4.xml","form_type":"4"}},{"id":3639755,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-02-22T18:45:15.000Z","date":"2019-02-20","kind":"tax_withholding","acquired":false,"shares":72245,"price":3.2,"value":231184.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 2, 2016, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2018. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 20, 2019. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award."}],"balance_after":1712522,"source":{"system":"sec-edgar","filing":"0001209191-19-012774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119012774/doc4.xml","form_type":"4"}},{"id":3639754,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-02-22T18:45:15.000Z","date":"2019-02-20","kind":"grant","acquired":true,"shares":254205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 2, 2016, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2018. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, the achievement of which was certified on February 20, 2019. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award."}],"balance_after":1784767,"source":{"system":"sec-edgar","filing":"0001209191-19-012774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919119012774/doc4.xml","form_type":"4"}},{"id":3835017,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-08-23T17:11:11.000Z","date":"2018-08-21","kind":"exercise","acquired":false,"shares":43000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. The exercised stock options reported on this Form 4 were due to expire on November 11, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested and became exercisable in equal quarterly installments over three years following the grant date of November 12, 2008."}],"balance_after":0,"derivative":{"exercise_price":0.47,"expiration_date":"2018-11-11","underlying":"Common Stock","underlying_shares":43000},"source":{"system":"sec-edgar","filing":"0001209191-18-048223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118048223/doc4.xml","form_type":"4"}},{"id":3835016,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-08-23T17:11:11.000Z","date":"2018-08-21","kind":"sale","acquired":false,"shares":43000,"price":3.75,"value":161250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. The exercised stock options reported on this Form 4 were due to expire on November 11, 2018."}],"balance_after":1530562,"source":{"system":"sec-edgar","filing":"0001209191-18-048223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118048223/doc4.xml","form_type":"4"}},{"id":3835015,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-08-23T17:11:11.000Z","date":"2018-08-21","kind":"exercise","acquired":true,"shares":43000,"price":0.47,"value":20210.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. The exercised stock options reported on this Form 4 were due to expire on November 11, 2018."}],"balance_after":1573562,"source":{"system":"sec-edgar","filing":"0001209191-18-048223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118048223/doc4.xml","form_type":"4"}},{"id":3898990,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-06-11T19:06:09.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":591510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in equal quarterly installments over three years from the date of grant."}],"balance_after":591510,"derivative":{"exercise_price":2.7,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":591510},"source":{"system":"sec-edgar","filing":"0001209191-18-037098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118037098/doc4.xml","form_type":"4"}},{"id":3898989,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-06-11T19:06:09.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":305556,"price":2.7,"value":825001.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents grant of restricted stock units made under the 2008 Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant."}],"balance_after":1530562,"source":{"system":"sec-edgar","filing":"0001209191-18-037098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118037098/doc4.xml","form_type":"4"}},{"id":3898988,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-06-11T19:06:09.000Z","date":"2018-06-07","kind":"tax_withholding","acquired":false,"shares":32031,"price":2.7,"value":86483.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award."}],"balance_after":1225006,"source":{"system":"sec-edgar","filing":"0001209191-18-037098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118037098/doc4.xml","form_type":"4"}},{"id":3906317,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-06-05T17:53:09.000Z","date":"2018-06-02","kind":"tax_withholding","acquired":false,"shares":34402,"price":2.69,"value":92541.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award."}],"balance_after":1257037,"source":{"system":"sec-edgar","filing":"0001209191-18-035890","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118035890/doc4.xml","form_type":"4"}},{"id":3914488,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-05-30T17:54:35.000Z","date":"2018-05-28","kind":"tax_withholding","acquired":false,"shares":13480,"price":2.43,"value":32756.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to settle tax liability in connection with the vesting of a previously granted restricted stock unit award."}],"balance_after":1291439,"source":{"system":"sec-edgar","filing":"0001209191-18-034228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118034228/doc4.xml","form_type":"4"}},{"id":3935482,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-14T18:23:22.000Z","date":"2018-05-11","kind":"exercise","acquired":false,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested in equal quarterly installments over the three-year period following the grant date of May 14, 2008, and were due to expire on May 13, 2018."}],"balance_after":0,"derivative":{"exercise_price":0.85,"expiration_date":"2018-05-13","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001209191-18-029995","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118029995/doc4.xml","form_type":"4"}},{"id":3935481,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-05-14T18:23:22.000Z","date":"2018-05-11","kind":"tax_withholding","acquired":false,"shares":30052,"price":2.52,"value":75731.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares used to cover payment of exercise price and tax liability for the underlying stock options that were exercised and held."}],"balance_after":1304919,"source":{"system":"sec-edgar","filing":"0001209191-18-029995","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118029995/doc4.xml","form_type":"4"}},{"id":3935480,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-05-14T18:23:22.000Z","date":"2018-05-11","kind":"exercise","acquired":true,"shares":82500,"price":0.85,"value":70125.0,"ownership":{"direct":true},"balance_after":1334971,"source":{"system":"sec-edgar","filing":"0001209191-18-029995","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118029995/doc4.xml","form_type":"4"}},{"id":4034835,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-02-26T17:46:55.000Z","date":"2018-02-22","kind":"tax_withholding","acquired":false,"shares":37001,"price":2.2,"value":81402.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 28, 2015, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2017. The number of shares acquired represent the total number of shares earned upon achievement of two performance goals, the achievement of which was certified on February 22, 2018. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award."}],"balance_after":1252471,"source":{"system":"sec-edgar","filing":"0001209191-18-013505","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118013505/doc4.xml","form_type":"4"}},{"id":4034834,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-02-26T17:46:55.000Z","date":"2018-02-22","kind":"grant","acquired":true,"shares":113835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 28, 2015, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three year performance period ended December 31, 2017. The number of shares acquired represent the total number of shares earned upon achievement of two performance goals, the achievement of which was certified on February 22, 2018. The shares disposed represents the number of shares withheld to settle tax liability in connection with the vesting of the performance stock unit award."}],"balance_after":1289472,"source":{"system":"sec-edgar","filing":"0001209191-18-013505","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919118013505/doc4.xml","form_type":"4"}},{"id":4286068,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-06-12T17:43:11.000Z","date":"2017-06-07","kind":"grant","acquired":true,"shares":338115,"price":2.66,"value":899385.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"This amendment is filed solely to correct \"D\" in Column 4 in the original Form 4 filed on June 9, 2017 to \"A.\""}],"balance_after":1175637,"source":{"system":"sec-edgar","filing":"0001209191-17-039253","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117039253/doc4a.xml","form_type":"4/A","original_submission_date":"2017-06-09"}},{"id":4287478,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-06-09T16:33:32.000Z","date":"2017-06-07","kind":"grant","acquired":true,"shares":725751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options vest in equal quarterly installments over three years from the date of grant."}],"balance_after":725751,"derivative":{"exercise_price":2.66,"expiration_date":"2027-06-07","underlying":"Common Stock","underlying_shares":725751},"source":{"system":"sec-edgar","filing":"0001209191-17-038901","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117038901/doc4.xml","form_type":"4"}},{"id":4287477,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-06-09T16:33:32.000Z","date":"2017-06-07","kind":"grant","acquired":false,"shares":338115,"price":2.66,"value":899385.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents grant of restricted stock units made under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant."}],"balance_after":1175637,"source":{"system":"sec-edgar","filing":"0001209191-17-038901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117038901/doc4.xml","form_type":"4"}},{"id":4287476,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-06-09T16:33:32.000Z","date":"2017-06-02","kind":"tax_withholding","acquired":false,"shares":38034,"price":2.57,"value":97747.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents shares withheld to settle tax liability in connection with the vesting of a restricted stock unit award that was previously granted on June 2, 2016."}],"balance_after":837522,"source":{"system":"sec-edgar","filing":"0001209191-17-038901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117038901/doc4.xml","form_type":"4"}},{"id":4287475,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-06-09T16:33:32.000Z","date":"2017-05-29","kind":"tax_withholding","acquired":false,"shares":3390,"price":2.51,"value":8508.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares withheld to settle tax liability in connection with the vesting of a restricted stock unit award that was previously granted on May 29, 2014."}],"balance_after":875556,"source":{"system":"sec-edgar","filing":"0001209191-17-038901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117038901/doc4.xml","form_type":"4"}},{"id":4287474,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-06-09T16:33:32.000Z","date":"2017-05-28","kind":"tax_withholding","acquired":false,"shares":14903,"price":2.51,"value":37406.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld to settle tax liability in connection with the vesting of a restricted stock unit award that was previously granted on May 28, 2015."}],"balance_after":878946,"source":{"system":"sec-edgar","filing":"0001209191-17-038901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117038901/doc4.xml","form_type":"4"}},{"id":4287473,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-06-09T16:33:32.000Z","date":"2017-02-22","kind":"tax_withholding","acquired":false,"shares":1763,"price":2.37,"value":4178.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 22, 2013, Mr. Apple was granted a performance stock unit award that was contingent upon the Company achieving certain performance goals over a three year performance period ended December 31, 2016. The shares reported here represent the total number of shares that were earned upon the achievement and certification of one of the performance goals, which was net settled. The shares disposed represents the shares withheld to settle tax liability in connection with the vesting of the performance stock unit award."}],"balance_after":893849,"source":{"system":"sec-edgar","filing":"0001209191-17-038901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117038901/doc4.xml","form_type":"4"}},{"id":4287472,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-06-09T16:33:32.000Z","date":"2017-02-22","kind":"grant","acquired":true,"shares":5612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 22, 2013, Mr. Apple was granted a performance stock unit award that was contingent upon the Company achieving certain performance goals over a three year performance period ended December 31, 2016. The shares reported here represent the total number of shares that were earned upon the achievement and certification of one of the performance goals, which was net settled. The shares disposed represents the shares withheld to settle tax liability in connection with the vesting of the performance stock unit award."}],"balance_after":895612,"source":{"system":"sec-edgar","filing":"0001209191-17-038901","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117038901/doc4.xml","form_type":"4"}},{"id":4358888,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-04-05T17:26:24.000Z","date":"2017-04-05","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.  The exercised stock option reported on this Form 4 was due to expire on May 10, 2017."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested and became exercisable in equal quarterly installments over three years following the grant date of May 10, 2007."}],"balance_after":0,"derivative":{"exercise_price":1.65,"expiration_date":"2017-05-10","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-17-025766","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117025766/doc4.xml","form_type":"4"}},{"id":4358887,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-04-05T17:26:24.000Z","date":"2017-04-04","kind":"exercise","acquired":false,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.  The exercised stock option reported on this Form 4 was due to expire on May 10, 2017."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested and became exercisable in equal quarterly installments over three years following the grant date of May 10, 2007."}],"balance_after":3000,"derivative":{"exercise_price":1.65,"expiration_date":"2017-05-10","underlying":"Common Stock","underlying_shares":37000},"source":{"system":"sec-edgar","filing":"0001209191-17-025766","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117025766/doc4.xml","form_type":"4"}},{"id":4358886,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-04-05T17:26:24.000Z","date":"2017-04-05","kind":"sale","acquired":false,"shares":3000,"price":3,"value":9000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.  The exercised stock option reported on this Form 4 was due to expire on May 10, 2017."}],"balance_after":890002,"source":{"system":"sec-edgar","filing":"0001209191-17-025766","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117025766/doc4.xml","form_type":"4"}},{"id":4358885,"issuer":{"id":126887,"kind":"organization","name":"ANTARES PHARMA, INC.","symbol":"ATRS"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-04-05T17:26:24.000Z","date":"2017-04-05","kind":"exercise","acquired":true,"shares":3000,"price":1.65,"value":4950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.  The exercised stock option reported on this Form 4 was due to expire on May 10, 2017."}],"balance_after":893002,"source":{"system":"sec-edgar","filing":"0001209191-17-025766","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016169/000120919117025766/doc4.xml","form_type":"4"}}],"next_cursor":"2017-04-05T17:26:24.000000Z,4358885"}